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ABSTRACT 
 
It has been hypothesised that low frequency (1-5% MAF) and rare (<1% MAF) variants 
with large effect sizes may contribute to the missing heritability in complex traits. Here we report 
an association analysis of lipid traits (total cholesterol, LDL-cholesterol, HDL-cholesterol 
triglycerides) in up to 27,312 individuals with a comprehensive set of low frequency coding 
variants (ExomeChip), combined with conditional analysis in the known lipid loci. No new locus 
reached genome-wide significance. However, we found a new lead variant in 26 known lipid 
association regions of which 16 were >1000 fold more significant than the previous sentinel variant 
and not in close LD (6 had MAF < 5%). Furthermore, conditional analysis revealed multiple 
independent signals (ranging from 1-5) in a third of the 98 lipid loci tested, including rare variants. 
Addition of our novel associations resulted in between 1.5-2.5 fold increase in the proportion of 
heritability explained for the different lipid traits. Our findings suggest that rare coding variants 
contribute to the genetic architecture of lipid traits.  
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INTRODUCTION 
 
Genome-wide association studies (GWAS) have identified hundreds of mainly common variants 
that are robustly associated with cardiometabolic traits (1-4). For lipid levels, a series of large-
scale meta-analyses (N > 100,000) identified a total of 164 independent single nucleotide 
polymorphisms (SNPs) in 159 loci contributing to variation in plasma concentrations of total 
cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-
density lipoprotein cholesterol (HDL-C) (2, 3, 5-8). Blood lipid levels have an estimated 
heritability of 40-70% (9); however, variants reaching genome-wide significance explain only 
~15% of the heritable fraction for these traits (2, 3). The clinical relevance of these 164 SNPs of 
which 71 associate with more than one lipid trait, is underscored by  an overall excess of significant 
association signals for coronary artery disease (CAD), fasting glucose, type 2 diabetes, blood 
pressure traits and body mass index (BMI) among them (2). 
 
It has been hypothesised that low frequency (1-5% minor allele frequency (MAF)) and rare (<1% 
MAF) variants with larger effects may account in part for the missing heritability in complex traits 
(10, 11).  To test this hypothesis in relation to lipid traits we used the Illumina HumanExome 
Beadchip (ExomeChip), an array which provides comprehensive coverage of low frequency 
coding variants (nonsynonymous, splice-site and stop altering), to profile 27,312 individuals. The 
Exome array also includes most of the lead (or a proxy) GWAS variants in the 159 known lipid 
loci which allowed to assess the independent contribution of additional, mainly low frequency, 
coding variants in these loci by performing conditional analysis with the GCTA software.  
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RESULTS 
 
Single-marker analysis 
 
In our single-marker meta-analysis of ExomeChip (Illumina) data in 27,312 individuals 
(an overview of the study design is given in Figure 1), we did not find any new variant associated 
with a lipid trait at either a genome-wide threshold of significance (P<5×10-8) or an array-wide 
threshold of significance (P<2×10-7) outside the 159 previously reported loci (considering a 1Mbp 
window centered on the sentinel SNP).  
The 159 unique loci known to be associated with one or more lipid traits represent 247 
association signals (73 for HDL-C, 58 for LDL-C, 74 for TC and 42 for TG) (6, 8, 12-14).  The 
ExomeChip array does not have a good proxy of the reported sentinel SNP (2, 3) in 21 of the 159 
lipid loci (see Materials and Methods). In our study, we detected 209 association signals with a 
lipid trait (55 for HDL-C, 50 for LDL-C, 67 for TC and 37 for TG) at P<0.01 (nominal 
significance; direction of effect same as published (2)) in 135 of the 159 unique lipid loci 
(Supplementary Table 1). Of the remaining 24 loci, 9 had no lead SNP or a proxy on the 
ExomeChip, 4 had the lead SNP or proxy fail QC, and 11 did not show a nominal association in 
our study.  
Further assessing the results of our single-marker analysis, we found that in about half (n= 
98) of the 209 association signals (26 for HDL-C, 17 for LDL-C, 35 for TC and 20 for TG), the 
lead SNP was either the published one or a highly linked proxy (r2 > 0.8; Supplementary Table 1); 
in two instances the proxy is a putative functional variant (rs2792751 in GPAM for LDL-C and 
rs35332062 in MLXIPL for TG) (Supplementary Table 1). In many loci our top hit was different 
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than the previously published lead SNP (this study) and not in close LD (r2 < 0.8) (Supplementary 
Table 1). Table 1 lists the 27 most significant of these associations (P<10-4) of which 8 are due to 
low frequency or rare coding variants. Interestingly, for 16 of these 27 association signals, the new 
sentinel variant was >1000 fold more significant than the previously published one. These results 
were also corroborated with one exception by conditional and joint analyses (see below); SNP 
rs5015480, a downstream variant in CYP26A1 previously reported for T2D (15), was not 
significant in the joint analysis. For the remaining 11 signals the new sentinel variant was only 
marginally more significant than the previously published one (includes two low frequency 
variants in LPA and KDM2B).  
Among the 27 association signals (Table 1), four variants had not been previously 
associated with a lipid trait. Two of them had a 1000-fold more significant association for TG 
levels than the previous sentinel SNP: rs72836561 a missense variant in CD300LG (p.R82C) and 
rs3094216 a synonymous variant (p.C448=) in CDSN. The other two variants were rs3751813 (TG 
association) an intronic variant in the FTO gene andrs34606562 (TC association) a synonymous 
change (p.L1174=) in KDM2B both of which overlap a strong peak for H3K27Ac which marks 
active regulatory elements. In the LPA locus, the missense variant rs3798220 (p.I1891M), 
previously associated with Lp(a) lipoprotein levels and CAD (16) had the strongest signal for 
LDL-C.  
In 15 of the 135 lipid loci with an association signal in our data (P < 0.01), we lacked the 
published lead SNP or a proxy (12 not on the ExomeChip and 3 QC failures; Supplementary Table 
1, column AJ) and therefore we were unable to undertake a direct comparison of the strength of 
association between our top hit and the published one. However, in one such locus, ABCA8, which 
is associated with HDL-C (2, 3), we found a missense variant (rs77542162; Cys1319Arg; 1.57% 
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MAF) associated with both LDL-C (P=6.40×10-13) and TG (P=6.23×10-11) but not HDL-C 
(P=0.46) located in the ATP-binding cassette, sub-family A (ABC1), member 6 (ABCA6) gene 
(Supplementary Table 1). ABCA6 encodes a membrane-associated protein and is located together 
with ABCA8 and three other ABC1 family members on 17q24. ABCA6 may play a role in 
macrophage lipid homeostasis (17) and in intercellular lipid transport processes in vascular 
endothelial cells (18). 
 
Conditional analysis 
 
We next undertook conditional analysis which looks for association signals that are 
independent of the lead SNP from the unconditional analysis, in the 135 unique loci harbouring 
209 lipid association signals at a nominal significance level of P<0.01 (boundaries are listed in 
Supplementary Table 2) using the GCTA software (19) and meta-analysis summary statistics from 
all 27,312 samples. We considered a signal from the conditional analysis to be significant if it 
passed a Bonferroni correction threshold based on the number of SNPs tested across the locus 
examined (Supplementary Table 2). Therefore only loci which had a lead SNP with P 
unconditional < the locus-wide Bonferroni threshold for multiple testing (i.e. based on the number 
of tested SNPs per locus), were amenable to conditional analysis. Based on the threshold calculated 
for each locus (Supplementary Table 2), it was possible to examine 98 of the 209 lipid association 
regions for a secondary signal (see Materials and Methods; Supplementary Table 1). We found 31 
(31.6%) of these association regions to have at least one additional independent signal. In total, we 
identified 89 independent signals (29 for HDL-C, 16 for LDL-C, 19 for TC and 25 for TG) in the 
31 association regions (Table 2 and Supplementary Table 3) corresponding to the 31 sentinel SNPs 
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from the unconditional analysis and 58 SNPs from the subsequent rounds of conditional analysis. 
The largest number of independent signals per locus was five, in the APOA1 locus for HDL-C as 
well as in the APOB and APOE loci for LDL-C (the latter illustrated in Supplementary Figure 1). 
Approximately 30% of the 89 independent variants were either low frequency (13; 14.6%) or rare 
variants (14; 15.7%), (Supplementary Table 1).  
Out of the 58 additional signals identified from the conditional analysis, 42 have previously 
been associated with a lipid trait (34 reported for the investigated lipid trait and 8 for a lipid trait 
other than the investigated one; Supplementary Table 3) and 16 have not been previously 
associated with any lipid trait (Table 2). Among the 34 lipid signals previously reported, two 
variants, rs439401 in APOE (TC) and rs35120633 in APOA1 (TG and HDL-C), showed an 
increase in their effect size after conditioning for the top hit in the corresponding region. In both 
instances, the very strong association signal of the lead SNP in the region (e.g. rs7412 P=7.43×10-
145 in the APOE locus) appears to partially mask the weaker secondary signal.  In the unconditional 
analysis, SNP rs439401 had an effect size (β) of -0.051 per T allele (P=1.77×10-8) whereas after 
conditioning on rs7412 the β doubled to -0.103 (P=3.70×10-31); this variant has been associated 
with HDL-C and TG as a bivariate phenotype (20). Similarly, the association of rs35120633 with 
TG and HDL-C (unconditional P=2.67×10-40 and P=2.02×10-9 respectively) became stronger after 
conditioning on rs2266788 (P=5.21×10-46 and P=1.38×10-10 respectively).  
 
Of the 16 conditional signals not previously associated with a lipid trait, 10 are rare variants 
(Table 2). These variants are missense except rs76353203 (MAF 0.04%; β=-1.258 per T allele) 
which introduces a stop codon in APOC3 (Arg19TER) and is known to cause 
hyperalphalipoproteinemia 2 (HALP2). At several loci, conditional analysis identified variants 
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with much larger effect sizes than the sentinel SNP e.g. missense variant rs116329129 
(rs116329129:T>C, p.V280A; MAF 0.03%) in BANK1 which was associated with HDL-C, had a 
β of -1.835 per C allele compared to -0.104 for the lead variant rs13107325 (MAF 6.02%) which 
is located in SLC39A8. The B-cell scaffold protein with ankyrin repeats 1 (BANK1) gene encodes 
a B-cell-specific scaffold protein involved in B-cell receptor-induced calcium mobilization from 
intracellular stores. Variants in BANK1 have been associated with susceptibility to systemic lupus 
erythematosus (21). Similarly, the missense variant rs139788907 (MAF 0.03%) in the 
phospholipase A2, group IVF (PLA2G4F) gene (rs139788907:A>G, p.L326P; deleterious change 
per SIFT) which was associated with TG levels, had a β=1.665; ~1.98 mmol/l per G allele) 10-
fold higher than that of the intronic lead variant rs2412710 (MAF 1.8%; β=0.165; 0.20 mmol/l per 
G allele) which is located in CAPN3. PLA2G4F encodes a calcium-dependent phospholipase A2 
that selectively hydrolyzes glycerophospholipids in the sn-2 position.  
 
Joint analysis 
 
Regional analyses can determine the specific contribution that each locus makes to the trait 
heritability. The iterative rounds of conditional analyses within GCTA described above enabled 
the identification of independently associated variants at each locus. Joint analyses can 
simultaneously estimate the effects of each of these significant variants adjusted for all other 
effects.  
The joint analyses were performed in both the discovery studies with appropriate ethical 
approval for sharing individual level data (16 of the 19 cohorts; N=24,894) and in the replication 
studies (4 cohorts; N=9,029), in order to (i) validate the original conditional analyses based on 
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GCTA regarding the handling of rare and low-frequency variants as well as check for any impact 
of sample size difference and (ii) confirm consistency between the discovery and replication 
studies, to ensure that the replication data is sufficiently concordant to be used for a risk score 
analyses (see below).  
Over 95% of the variants that were significant in the conditional analyses also had P<0.05 
in the joint analyses (29/29 for HDL-C; 17/18 for LDL-C; 18/19 for TC; and 18/20 for TG) 
(Supplementary Table 4).  A comparison of the βs between conditional and joint analyses (Figure 
2) revealed close agreement between the two analyses, with almost perfect directional consistency 
(55 out of 56 variants). Comparison of the p-values from each analysis (Figure 2) also showed 
close agreement for most variants despite a difference in sample size between the two analyses 
and the more conservative nature of the joint tests.  Importantly, the relationship between p-values 
did not appear to depend on MAF, and none of the variants with noticeably discordant p-values 
was rare or of low frequency. Of the four variants with P>0.05 we excluded rs5015480 and 
rs2068888 (TG signals in CYP26A1) from further analyses but retained rs3208856 (APOE-LDL) 
and rs920915 (LIPC-TC) given that they are established associations. In summary, we found good 
concordance between the joint and conditional analyses within the discovery studies. 
Joint analysis in the replication studies detected an effect in the same direction for 91.8% 
of the variants (Supplementary Table 4), showing good concordance between the discovery and 
replication data sets.  
 
Locus specific genetic score analysis 
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Next we calculated an overall genetic risk score association for each region except 
CYP26A1 (see joint analysis above), assessing the combined effects of all independent variants 
within a locus. In such analyses, the score is weighted by the effect sizes of each included variant. 
We used the beta estimates from the conditional analyses as risk score weights and performed the 
analyses in the replication set which comprised four independent studies (N=9,029). It is 
paramount to use an independent data set in order to minimise any bias. 
 
The genetic score analyses identified several strong effects (Table 3; effect estimates are 
from the unweighted model and are expressed as per 1-allele increment); for example, in the CETP 
locus each trait-increasing allele associated with 12.4% of an SD (~0.06 mmol/l) increase in HDL-
C accounting for 3.1% of the overall trait variation.  We also note the PCSK9 locus in which each 
trait-increasing allele was associated with 19.2% of an SD (~0.18 mmol/l) increase in LDL-C, but 
this region accounted for only 0.4% of the variation.  PCSK9 was also associated with a large 
effect on TC (16.6% of an SD; 0.18 mmol/l per trait-increasing allele), and explained 0.3% of the 
variation.  For TG, the strongest effect was found at the APOA1 locus (17.2% of an SD; ~0.20 
mmol/l per trait-increasing allele accounting for 1.7% of the variation). Cumulatively per trait, all 
regions tested accounted for 6.3% (HDL-C), 2.9% (LDL-C), 2% (TC), and 3.8% (TG) of the 
variation (Table 3). 
 
Heritability 
 
First, we assessed heritability in the 135 unique known lipid loci which reached P < 0.01 
in our study, considering only the published lead SNP (or proxy) and estimated a 7.12% heritability 
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for HDL-C, 6.52% for LDL-C, 7.03% for TC and 6.31% for TG. When we considered for the same 
loci all independent sentinel SNPs from our study (lead and secondary signals as per 
Supplementary Table 1) we observed a between 1.5 and 2.5 -fold increase in the heritability 
estimates (14.73% for HDL-C, 15.06% for LDL-C, 13.49% for TC and 9.62% for TG). 
Finally, after exclusion of the CYP26A1 locus (2 variants) we assessed the incremental 
contribution of the multiple independent signals we detected by conditional analysis in the 
remaining 30 loci (87 in total) to heritability. Accounting for all signals per locus increased their 
contribution to heritability estimates for all lipid traits; 4.78% vs. 11.07% (HDL-C), 1.26% vs. 
8.89% (LDL-C), 2.29% vs. 7.00% (TC), and 5.70% vs. 6.55% (TG) when comparing heritability 
estimates based on the known sentinel SNPs alone.  
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DISCUSSION 
We undertook an association study in 27,312 individuals to test the hypothesis that low-
frequency and rare coding variants contribute to the genetic architecture of the four main lipid 
traits, TC, TG, HDL-C and LDL-C explaining some of the missing heritability in large-scale 
genetic studies of common variants (2, 3). Of the 203,350 non-synonymous (missense, nonsense, 
splice-site, and frameshift) variants present on the ExomeChip, ~64,000 had a minor allele 
frequency above 0.1% to allow for single variant association testing. We did not find any new loci 
to be significant at the genome-wide level of significance in addition to the 159 loci known to be 
robustly associated (P<5×10-8) with plasma concentrations of these lipid traits. Our findings are in 
agreement with other recent studies that have used exome sequencing, exome arrays or 1000 
Genome Project imputed GWAS studies to investigate circulating blood lipid levels or related 
traits (23-25) that have also not  found new loci harbouring low frequency / rare coding variants 
with large effect sizes (23-26).  
To extend our assessment of the impact of low frequency / rare coding variation on lipid 
levels, we also examined the 159 known lipid (2, 3) by assessing the results of both the single-
marker and conditional analyses at these loci; for the latter we took advantage of the presence of 
previously reported index lipid-associated variant (or a good proxy) at 135 of these loci on the 
ExomeChip. We note that a recent study by the ENGAGE consortium (26) has identified an 
additional 10 unique loci associated with lipid traits but the Exome-chip does not harbour the 
sentinel SNP or a good proxy to allow conditional analysis (7 loci have a variant on the array 
reaching nominal significance; Supplementary Table 5). Interestingly, in 16 of the loci tested in 
our study we detected lead variants having an index signal at least 1000-fold more significant than 
the previously-reported sentinel SNP (Table 1); these included variants previously reported in the 
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literature for either the investigated and other lipid traits (10) or for lipid traits other than the 
investigated one (4) as well as two variants not previously associated with a lipid trait (rs3094216 
and rs72836561). SNP rs3094216 (MAF 77.6%) is located in the CDSN gene, corneodesmosin, 
which encodes a protein found in human epidermis and other cornified squamous epithelia. 
Furthermore, rs3094216, is in strong LD with rs3095318 a missense variant in CDSN (p. M18L).   
Mutations in CDSN are known to cause peeling skin syndrome (PSS) type B disease, a rare 
recessive genodermatosis whereas a common synonymous SNP (rs1062470) has been associated 
with psoriasis (27). The other variant, rs72836561, is a low frequency missense variant in 
CD300LG (p.R82C; MAF 2.69%). CD300LG encodes the CD300 molecule–like family member 
G protein; a type I cell surface glycoprotein that contains a single immunoglobulin V–like 
domain and has a role in lymphocyte binding and transmigration.  
In addition to rs72836561 (CD300LG) described above, two more low frequency or rare 
coding variants had not been previously associated with a lipid trait: the missense variant rs3798220 
(p. I1891M) in LPA which was associated with LDL-C levels and rs34606562 a synonymous 
change (p.L1174) in KDM2B associated with TC levels.  KDM2B encodes a member of the F-box 
protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-
box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs 
(SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. KDM2B gene 
has been recently associated with methylation in adipose tissue and our lead variant (rs34606562) 
which overlaps a strong peak for H3K27Ac, is located 95.6 kb away of the methylation probe 
(cg13708645) used to detect it (28). In total, after taking in to consideration the results of the 
conditional analyses, we found 27 low frequency (13) or rare coding variants (14) to be associated 
with lipid levels. Interestingly, we observed higher effect sizes for variants with minor allele 
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frequency below 3% compared to more common SNPs (Supplementary Figure 2; power 
calculations based on total cholesterol showed 80% power to detect a minimum effect size of 0.125 
at 1% MAF).  However, this may reflect the fact that our study only had power to detect rare 
variants with higher effect sizes. 
Overall, our study identified 14 missense variants not previously reported to be associated 
with a lipid trait. Two of them, rs3798220 and rs72836561, were new sentinel SNPs (Table 1) and 
the remaining 12 were identified as distinct additional signals through conditional analysis 
(rs116329129, rs138407155, rs140029729, rs200684324, rs117623631, rs5167, rs36053277, 
rs145814749, rs1132899, rs5742904, rs139788907, rs5880; Table 2). In total, 21 unique lipid loci 
(28 regions of association; all lipid traits) where we had the known sentinel SNP on the ExomeChip 
array had a missense variant as lead SNP (P < 10-4) (Supplementary Table 1). 
Our joint analyses validated the results from the conditional analyses showing that the 
GCTA software is also suitable for handling low-frequency variants, despite being designed for 
common variant analysis. We removed from further analyses one locus for TG, CYP26A1, based 
on the results of the joint analysis as both variants had Pj>0.05. This was partly due to using a 
random effect model for rs2068888 which showed significant heterogeneity. In the genetic score 
analyses, estimating the combined effect of genetic variants within each locus, we observed 
substantial overall effects on lipid traits in several loci (CETP, PCSK1, APOA1); for example, in 
the CETP locus each trait-increasing allele associated with 12.4% of an SD (~0.06 mmol/l) 
increase in HDL-C accounting for 3.1% of the overall trait variation.    
As shown by others (26, 29-32), we found a substantial increase in the explained variance 
when we assessed heritability estimates based on the 209 variants (all traits) identified by both the 
unconditional and conditional analysis compared to the published lead SNPs in the corresponding 
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135 loci. In some loci the inclusion of new independent secondary signals contributes only 
marginally to heritability estimates. For example, in the APOE locus, 96.26% of the locus-specific 
heritability for TC was explained by rs7412 and rs769449 (72.41% and 23.84% respectively) 
which capture the APOE 2/3/4 alleles. SNP rs7412 was the most significant variant for TC and 
LDL-C (P=7.43×10-145 and P=1.43×10-80 respectively) in our study whereas rs769449, a proxy of 
rs429358 (r2 0.82), was the lead variant for HDL-C (P=7.29×10-13) and a secondary independent 
signal for TC and LDL-C. For LDL-C, these two variants explain 91.51% of the locus-specific 
heritability (70.95% and 20.56% respectively). Among the three additional secondary signals in 
the APOE locus for LDL-C, the low-frequency missense variant rs3208856 explained most of the 
remaining variance (7.55%). Overall the inclusion of low frequency / rare variants appear to 
significantly impact heritability estimates, for example, we observed a  seven-fold increase in 
LDL-C variance explained cumulative when comparing only the loci that harboured secondary 
signals. But rare coding variants with large effect sizes are not likely to explain the overall missing 
fraction of the genetic component of lipid traits.   
Some important limitations of our study merit to be highlighted. First, the list of tested 
coding variants is by no means exhaustive especially at the rare end of the frequency spectrum. 
Hamond and colleagues, estimated the Exome array to capture 72.5% and 66.2% of loss-of-
function (LoF) and missense variation with MAF 0.5 and 0.1%, respectively (33). Second, our 
study does not have sufficiently high power to detect very low-frequency and / or rare variants 
with small effect sizes.  Power calculations for our study (based on total cholesterol) showed that 
we had 80% power to detect a minimum effect size of 0.07 at a 3% MAF, 0.125 at 1% MAF, 0.4 
at 0.1% and 1.25 at 0.01% MAF. Therefore, even larger sample sizes will be required to identify 
new rare variants with small effect sizes. 
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In conclusion, we demonstrate that low frequency / rare coding variants contribute to the 
genetic architecture and heritability of lipid traits despite a paucity of low frequency coding 
variants with large effect sizes.  
 
MATERIALS AND METHODS 
 
Samples and Phenotypes 
We collected summary statistics for ExomeChip SNPs from 19 studies (N~26,000). Among these, 
17 studies consisted primarily of individuals of European ancestry, and two studies consisted of 
individuals of South Asian descent (see Supplementary Note and Supplementary Table 6 for 
details). Both population-based studies and case-control studies were included; for case-control 
studies, cases and control samples were analysed separately. Results for blood lipid levels were 
provided in mmol/l units and trait residuals within each cohort were adjusted for age, age2, and 
sex, and then inverse-rank normalized. Individuals known to be on lipid-lowering medication were 
excluded from the analysis (Supplementary Table 6). 
 
Genotyping 
A total of 247,870 genetic variants were genotyped using the Illumina ExomeChip array. The 
ExomeChip variants comprise 203,350 non-synonymous, 10,690 splice and 5,641 stop variants as 
well as 4,761 SNPs from the GWAS NHGRI catalogue. Genotypes were called with GenCall, 
subjected to QC (Supplementary Table 7) to remove poor quality samples and finally recalled 
using zCall, an algorithm optimised for rare variant detection (34). Average standard errors for 
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association statistics from each study were plotted against study sample size to identify outlier 
studies. Allele frequencies were inspected to ensure all analyses used the same strand assignment. 
 
Primary linear regression analysis  
Analyses were performed for each trait (HDL-C, LDL-C, TC and TG) using the assumption of an 
additive genetic model. Individual SNP association tests were performed using linear regression 
with the inverse normal transformed trait values as the dependent variable and the expected allele 
count for each individual as the independent variable. Explicit adjustments for population sub-
structure using principal components (35) were carried out. These analyses were performed using 
a range of analytical software (Supplementary Table 7). 
 
Meta-analysis  
An inverse-variance weighted meta-analysis using a fixed effect model was performed, using both 
GWAMA (36) and METAL (37) and results were compared and checked for consistency. SNPs 
were excluded from the meta-analysis if they had MAF>5% and were absent in >90% of the 
samples or had MAF<5% and were absent in >25% of the samples and present in at least two 
studies and/or failed cluster plot evaluation. Heterogeneity was evaluated using Cochran’s Q- and 
I² statistic. For SNPs with non-significant heterogeneity (P for Q>0.01), we report the results from 
the fixed effect model whereas in the presence of significant heterogeneity (P for Q<0.01) we used 
a random effect model. Signals were considered to be novel if they reached a genome-wide 
significance (P<5×10-8) in the meta-analysis and were > +/- 500 kB away from the nearest 
previously described lipid locus. For the previously published lipid loci we considered replication 
22 
 
at nominal significance level of P<0.01. We note that for 28 loci the published lead SNP was not 
present on the ExomeChip (21) or were removed during QC (Supplementary Table 8).  
 
Approximate conditional analysis 
Conditional analysis was implemented in GCTA (19) using meta-analysis summary statistics from 
all 27,312 samples. A subset of 11,396 samples (part of the contributing studies: BC1958, 
BRIGHT, FIA3, EPIC and GoDARTS) of European origin was used as a reference panel for LD 
calculations. We considered in total 159 published lipid loci (2, 3) and 247 lipid association signals 
(73 for HDL-C, 58 for LDL-C, 74 for TC and 42 for TG). SNPs failing the cluster plot inspection 
were replaced by the next most significant SNP in the locus. Subsequent rounds of stepwise 
conditional analysis were performed in each locus until no significant SNP could be identified. 
The level of significance for each round of the conditional analysis was defined as 0.05/(locus SNP 
content – conditional SNPs) to account for multiple testing (Supplementary Table 2). 
 
Joint analyses 
Joint analyses were performed for any loci identified in the conditional analyses as containing 
more than one statistically significant SNP. The joint tests estimated the associations between the 
phenotype and all statistically significant independent SNPs within a region simultaneously (by 
fitting one linear regression model per region).   
 
Locus specific genetic score analyses 
The genetic score analyses estimated the combined effect of all statistically significant SNPs 
within a region (Supplementary Table 2) by regressing a genetic score against the phenotype. 
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Genetic scores were derived in two ways: 1) by summing the number of trait-increasing alleles (as 
defined by the estimated directions of the SNPs effects in the conditional analyses) carried by each 
individual; and 2) by producing a weighted sum of the number of trait-increasing alleles against 
the phenotype (38). In this latter scenario, the genetic scores were weighted by multiplying 
genotypes by the corresponding estimated SNP effect (i.e. the “β”) from the conditional analysis. 
Joint tests and genetic score analyses were performed on the inverse-rank normalised trait values, 
which had been adjusted for age, age2 and sex. Adjustments for principal components were also 
made, where applicable, to control for any potential population stratification within each study.  
The joint analyses were run in a total of 20 cohorts (Nmax=33,923). Of these, 16 (N=24,894) 
contributed to the individual SNP meta- and conditional analyses and were considered “discovery” 
cohorts, while a further 4 cohorts (N=9,029) that did not contribute to the preceding analyses were 
also included as “replication” cohorts.  The genetic score analyses were only run in the replication 
cohorts in order to minimise bias, due to using weights estimated from the discovery meta-
analyses. Only studies with unrelated individuals were included in these analyses.  Studies with 
any missing data (i.e. where a SNP had been dropped during QC) within a particular region did 
not contribute to the overall result for that region.   
Linear regression tests and genetic score analyses were conducted separately by each study. Meta-
analyses were performed using the metafor package in R (39). Overall estimates of the proportion 
of variation explained by each region (“R2”) were derived by taking a weighted average over 
contributing studies (with weights based on sample size). 
 
Heritability 
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Heritability estimates were calculated using the multifactorial liability threshold model (40). The 
calculations are performed using the inverse normal transformed traits meta-analysis results, based 
on a population SD of 1 and under the additive genetic model assumption. All variants included in 
the heritability calculations per trait were not in LD (r2<0.3). 
 
URLs 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design 
http://www.metafor-project.org/ http://www.wvbauer.com 
The results of the meta-analysis are available upon request and will be made available at 
http://www.qmul.ac.uk/ExomeChip.Lipids.SummaryStatistics.zip 
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LEGENDS TO FIGURES 
 
Figure 1 legend: Flow diagram of the study  
 
Figure 2 legend: Comparison of results between conditional and joint analyses. Note that these 
figures do not include the lead SNP in each region (i.e. round > 0 means that variants from the 
conditional analysis are shown only), as the conditional analyses do not produce adjusted estimates 
of their effects in contrary to the joint analyses. 
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TABLES 
Table 1. New sentinel SNPs in known lipid loci (P<10-4) showing stronger association than the previously reported variant 
 
  New lead SNP  Published lead SNP  
Trait Locus(Gene; Amino Acid change) rsID 
Trait-
raising/ 
Other allele 
Public
ation 
Status 
%EAF N β SE p-value  rsID (r2) ¶ 
Trait-
raising/ 
Other allele 
%EA
F N β SE p-value  
 New lead SNP >1000 fold more significant than the published lead SNP 
HDL 
                  
LIPG (LIPG;N/S) rs779603474,5 G/A a 1.29 25373 0.289 0.040 6.42E-13  rs72419186 (0.006) T/G 83.82 25371 0.075 0.012 7.78E-10  
ANGPTL4(ANGPTL4
;E/K) rs116843064
4,5 A/G b 1.88 24406 0.254 0.034 6.79E-14  rs7255436
1,2,14 
(0.02) A/C 51.66 25375 0.021 0.009 1.95E-02  
LIPC rs18005881,2 T/C a 21.89 25375 0.138 0.011 1.12E-36  rs1532085
1,2 
(0.0004) A/G 40.26 25374 0.109 0.009 1.16E-31  
APOA1 rs22667881,8 A/G a 91.66 25375 0.115 0.016 3.29E-12  rs9641841,8 (0.5) C/G 80.45 25372 0.098 0.021 3.04E-06  
TRIB1 rs29540331 G/A a 70.47 25374 0.041 0.010 3.29E-05  rs29540291,2,10 (0.4) T/A 44.76 25375 0.016 0.009 6.92E-02  
APOE rs769449
1, 2, 
10,16 G/A b 88.08 25375 0.100 0.014 7.39E-13  rs4420638
1,11 
(0.6) A/G 81.15 21172 0.076 0.013 1.80E-09  
LDL 
APOE (APOE;R/C) rs74124,5 C/T a 92.79 24361 0.561 0.029 1.43E-80  rs44206381,11 (0.02) G/A 18.80 20158 0.200 0.013 3.15E-54  
PCSK9(PCSK9;(R/L) rs115911471,4,5 G/T a 98.35 24361 0.461 0.036 1.93E-37  rs24794091,13 (0.009) G/A 33.61 24361 0.042 0.010 2.14E-05  
CILP2 rs23041301,2,12 A/G a 91.06 24360 0.099 0.016 9.01E-10  rs104019691,2,14 (0.5) T/C 91.92 22547 0.119 0.028 1.62E-05  
APOA1 rs20752901,2 C/T a 8.26 27312 0.120 0.016 3.52E-14  rs9641841,8 (0.5) G/C 19.26 27309 0.097 0.020 2.26E-06  
TC 
FRMD5(MAP1A;P/L) rs557071004,5 T/C a 2.60 26483 0.186 0.028 6.87E-11  rs29292821,2 (0.4) T/A 4.86 26473 0.063 0.021 2.64E-03  
APOE(APOE;R/C) rs74124,5 C/T b 92.73 27312 0.423 0.017 7.43E-145  rs44206381,11 (0.02) G/A 19.09 23109 0.164 0.012 1.96E-42  
PCSK9(PCSK9;R/L) rs115911471,4,5 G/T b 98.39 27312 0.406 0.034 5.42E-32  rs24794091,13 (0.009) G/A 33.96 27312 0.039 0.009 2.57E-05  
MPP3(CD300LG;R/C
) rs72836561
4,5 T/C c 2.69 26484 0.133 0.027 1.21E-06  rs8077889
1,11 
(0.007) C/A 20.33 26484 0.005 0.011 6.69E-01  
APOA1 rs22667881,8 G/A a 8.34 26484 0.265 0.016 5.97E-61  rs9641841,8 (0.5) G/C 19.45 26481 0.230 0.037 7.99E-10  
WASF5P_HLAB(CD
SN) 
rs30942162, 7, 
,10, 16 A/G c 77.60 26484 0.052 0.011 3.66E-06  
rs22470561,2,10 
(0.08) C/T 75.18 26484 0.028 0.011 1.04E-02  
 New lead SNP nominally more significant than the published lead SNP  
HDL 
ABCA1 rs39050001,2 G/A a 86.23 25374 0.095 0.013 4.85E-13  rs18830251,2 (0.3) C/T 73.92 25374 0.074 0.010 6.85E-13  
MLXIPL rs11789791,8 C/T b 18.21 25375 0.055 0.012 3.10E-06  rs171457381,11 (0.5) T/C 12.03 25375 0.056 0.014 6.07E-05  
COBLL1 rs133892191,15 T/C b 38.05 25374 0.037 0.009 9.09E-05  rs123286751,8 C/T 12.08 25371 0.042 0.014 2.36E-03  
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(0.2) 
LDL 
BRAP(SH2B3;W/R) rs31845041,4,5 C/T a 56.67 24361 0.040 0.010 3.28E-05  rs110659871,6 (0.7) A/G 61.63 24361 0.036 0.010 2.04E-04  
MYLIP(MYLIP;N/S) rs93708674,5 A/G a 50.43 24158 0.038 0.009 3.52E-05  rs37573541,15 (0.3) C/T 76.91 24359 0.035 0.011 1.18E-03  
LPA(LPA;I/M) rs37982201,4,5 C/T c 1.57 24361 0.154 0.037 3.42E-05  rs1564348
1,2 
(0.001) C/T 16.55 24361 0.032 0.012 9.31E-03  
TC 
APOB rs5410411,6 A/G a 83.48 27312 0.141 0.012 2.29E-33  rs13671174,5 (0.06) A/G 31.96 27312 0.112 0.009 6.19E-33  
CETP rs15326241,2, 15 A/C a 44.13 27311 0.040 0.009 5.88E-06  rs37642611,13 (0.6) A/C 32.17 27312 0.041 0.009 1.03E-05  
HNF1A(KDM2B;L) rs34606562
7,10,
16 C/A c 99.99 6885 2.810 0.708 7.20E-05  
rs11692881,4,5,14 
(0.000009) C/A 34.67 27307 0.028 0.009 2.73E-03  
TG 
FTO rs37518132,9 T/G c 55.18 24410 0.037 0.009 5.77E-05  rs1121980
1,2 
(0.6) A/G 43.11 26484 0.027 0.009 2.56E-03  
CYP26A1 rs50154801,11,17 C/T c 55.75 26480 0.038 0.009 2.62E-05  rs2068888
1,11 
(0.00003) G/A 53.36 26483 0.037 0.009 3.97E-05  
 
Publication status a: previously published variants for the investigated and other lipid traits, publication status b: previously published 
variants for lipid traits other than the investigated one, publication status c: new variants (not published for any lipids trait) 
¶Pair wise LD estimation between the ExomeChip lead SNP and the published lead SNP was based on the reference panel used for the 
conditional analysis (n=11,396 samples). 
1NHGRI catalogue, 2intron variant, 3independent secondary hit in the conditional analysis, 4nonsynonymous variant, 5missense variant, 
6intergenic variant, 7synonymous variant,  83’ prime UTR variant, 9common variant, 10non-coding transcript variant, 11 downstream gene variant 
, 12splice region variant, 13upstream gene variant, 14nonsense-mediated mRNA decay transcript variant,  15regulatory region variant, 16non-
coding exon variant, 17did not reach significance threshold in joint analysis (Pj > 0.05; see text)  
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Table 2. New variants identified as independent signals in the approximate conditional analysis 
     Single SNP meta-analysis  Approximate conditional meta-analysis  
Trait Chromosme: Position rsID 
Trait-raising/ 
Other allele 
%EA
F β SE p-value 
 N β SE p-value Conditioned on Locus 
HDL 
4:102816487 rs1163291291, 4 T/C 99.97 1.835 0.448 4.23E-05  9023 1.842 0.448 3.99E-05 rs13107325 SLC39A8 
11:117112526 rs795541102,3 T/G 37.94 0.038 0.009 5.69E-05  24813 0.034 0.009 2.16E-04 rs2266788, rs35120633, rs186808413 APOA1 
11:116707044 rs1384071551,4 A/T 99.88 0.589 0.143 3.98E-05  20910 0.505 0.143 4.09E-04 rs2266788, rs35120633, rs186808413, rs79554110 APOA1 
15:58830639 rs1400297291,4 A/G 99.92 1.019 0.273 1.88E-04  8544 0.963 0.273 4.14E-04 rs1800588, rs10468017 LIPC 
15:58837989 rs2006843241,4 A/G 0.13 0.760 0.223 6.62E-04  7941 0.721 0.223 1.23E-03 rs1800588, rs10468017, rs140029729 LIPC 
18:47113165 rs1176236311,4 T/C 0.22 0.389 0.116 8.36E-04  17028 0.390 0.116 8.08E-04 rs77960347, rs4939883 LIPG 
19:45448465 rs51671,4,5 G/T 36.02 0.042 0.009 6.19E-06  25337 0.046 0.009 8.70E-07 rs769449 APOE 
19:45028231 rs360532771,4 G/A 99.62 0.304 0.079 1.14E-04  22141 0.289 0.079 2.43E-04 rs769449, rs5167 APOE 
LDL 
6:161018174 rs77706283,8 C/T 45.47 0.030 0.009 1.38E-03  23595 0.035 0.009 2.03E-04 rs3798220 LPA 
12:121660770 rs1458147491,4 G/A 99.91 0.768 0.205 1.85E-04  13946 0.768 0.205 1.85E-04 rs34606562 HNF1A 
19:45448036 rs11328991,4,5 T/C 47.49 0.033 0.009 3.37E-04  24201 0.037 0.009 4.71E-05 rs7412, rs769449, rs445925, rs3208856 APOE 
TC 2:21229160 rs57429041,4 T/C 0.05 1.676 0.260 2.53E-11  13764 1.679 0.260 2.38E-11 rs541041, rs1367117, rs533617 APOB 
TG 
2:27550967 rs104981711 A/G 59.83 0.053 0.009 5.42E-09  26031 -0.030* 0.007 2.54E-05 rs1260326 GCKR 
11:116701353 rs763532039,10 C/T 99.96 1.258 0.320 8.60E-05  11860 1.279 0.320 6.58E-05 rs2266788, rs35120633 APOA1 
15:42436237 rs1397889071,4 G/A 0.04 1.665 0.421 7.67E-05  6731 1.668 0.421 7.49E-05 rs2412710 CAPN3 
16:57015091 rs58801,4 C/G 5.09 0.085 0.021 3.85E-05  24330 0.078 0.021 1.33E-04 rs3764261 CETP 
 
1nonsynonymous variant, 2common variant, 3intron variant,  4missense variant, 5nonsense-mediated mRNA decay transcript variant, 6non-
coding exon variant, 7non-coding transcript variant, 8NHGRI catalogue, 9stop gained variant, 10splice region variant, 11synonymous 
rs7770628 has been previously published for LPA eQTL 
*change in the direction of the conditional effect 
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Table 3. Association results from the genetic score analyses estimating the combined effect of all statistically significant SNPs within a 
region by regressing a genetic score against each lipid trait 
   Replication studies 
Trait Locus rsIDs N β SE p-value R2 
HDL 
       
LPL rs328, rs268, rs13702, rs1801177 9025 0.098 0.010 1.07E-21 0.010 
ABCA1 rs3905000, rs1883025 9025 0.050 0.011 1.53E-05 0.003 
APOA1 rs2266788, rs35120633, rs186808413, rs79554110, rs138407155 9025 0.060 0.013 8.90E-14 0.003 
LIPC rs1800588, rs10468017, rs140029729, rs200684324 7634 0.116 0.013 6.19E-18 0.010 
CETP rs3764261, rs5880, rs9939224, rs5882 9025 0.124 0.007 1.12E-75 0.031 
LCAT rs2271293, rs4986970 9025 0.064 0.020 1.15E-03 0.001 
       
APOE rs769449, rs5167, rs36053277 9025 0.055 0.013 1.51E-04 0.003 
LDL 
ABCG5/8 rs6756629, rs4245791 8697 0.057 0.014 3.87E-05 0.002 
LPA rs7770628, rs3798220 8697 0.037 0.016 4.31E-05 0.001 
PCSK9 rs505151, rs11591147 8697 0.192 0.034 3.73E-14 0.004 
       
APOE rs1132899, rs3208856, rs445925, rs769449, rs7412 8697 0.116 0.013 5.13E-110 0.011 
APOB rs41288783, rs5742904, rs533617, rs541041, rs1367117 8697 0.099 0.011 1.57E-19 0.010 
TC 
ABCG5/8 rs4245791, rs6756629 9029 0.057 0.013 2.09E-05 0.003 
PCSK9 rs11591147, rs505151 9029 0.166 0.033 2.37E-11 0.003 
APOA1 rs2075290, rs35120633 9029 0.091 0.022 5.66E-05 0.002 
LIPC rs1532085, rs1800588, rs920915 9029 0.017 0.014 1.73E-02 0.000 
LIPG rs4939883, rs77960347 9029 0.063 0.019 4.72E-04 0.002 
APOE rs7412, rs439401, rs769449, rs445925 9029 0.046 0.011 4.05E-57 0.002 
APOB rs541041, rs1367117, rs533617, rs5742904 9029 0.086 0.011 2.30E-18 0.008 
TG 
LPL rs15285, rs268, rs1801177, rs328 8729 0.111 0.011 3.26E-26 0.013 
TRIB1 rs2954033, rs2954029 8729 0.049 0.009 7.72E-08 0.004 
       
APOA1 rs76353203, rs35120633, rs7350481, rs2266788 8729 0.172 0.015 2.70E-37 0.017 
       
LIPC rs1800588, rs1532085 8729 0.030 0.012 9.63E-03 0.001 
CETP rs5880, rs3764261 8729 0.035 0.015 2.87E-02 0.001 
GCKR rs1049817, rs1260326 8729 0.077 0.018 3.32E-17 0.002 
*Results taken from random-effects model (due to having p<0.01 for the Q statistic). Βetas, standard errors (SEs) and R2 estimates taken 
from the non-weighted models; betas are expressed as per 1-allele increment in the risk score, p-values estimated from the weighted models; 
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only regions with a p-value<0.05 are presented.  Note that R2 estimates were synthesised by taking a weighted average over contributing 
studies (with weights based on sample size).  
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ABBREVIATIONS 
MAF - Minor Allele Frequency 
SNP - Single Nucleotide Polymorphism 
GWAS - Genome-wide association studies 
TC - Total Cholesterol  
TG - Triglycerides  
LDL-C - low-density lipoprotein cholesterol  
HDL-C - high-density lipoprotein cholesterol 
CAD - Coronary Artery Disease 
CVD - Cardiovascular Disease 
QC - Quality Control 
LD - Linkage Disequilibrium 
